Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 19Lymphoma, Non-Hodgkin 11Hodgkin Disease 10Leukemia, Biphenotypic, Acute 8Multiple Myeloma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia 7Burkitt Lymphoma 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Neuroblastoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Anemia, Refractory, with Excess of Blasts 5Recurrence 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Breast Neoplasms 4Lymphoma, T-Cell 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Sarcoma 2Rhabdomyosarcoma 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Myelodysplastic-Myeloproliferative Diseases 2Medulloblastoma 2

Interventions

sargramostim 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Transplant-Related Hematologic Malignancy × Granulocyte Colony-Stimulating Factor × 1 year × Clear all
NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Northside Hospital, Inc.

Phase 2 Recruiting
38 enrolled

Transplant-Related Hematologic Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡